Pinnacle Hill

What Pinnacle Hill does

Pinnacle Hill is a drug discovery and development partnership that accelerates the translation of academic research into clinical therapeutics. Established in October 2018 as a joint venture between the University of North Carolina at Chapel Hill and Deerfield Management, the company operates as a Delaware LLC headquartered at 345 Park Avenue South in New York. Deerfield has committed up to $65 million in targeted funding, while UNC-Chapel Hill provides access to its faculty research base. Projects are approved and directed by a joint steering committee composed of leadership from both organizations.

The company's core offering is a research funding and operational support model that selects early-stage translational projects at UNC-Chapel Hill and advances them toward investigational new drug (IND) enabling studies. Each selected project receives full development plans with targeted milestones, funding for IND-enabling work, project management oversight, and access to veteran drug development scientists. The CSO, Jon Collins, PhD (a 24-year GlaxoSmithKline veteran with 80 publications and 16 patents covering six clinical compounds), leads scientific direction. To date, Pinnacle Hill has funded two projects: multiple myeloma research led by Lindsey James (December 2019) and Angelman syndrome research led by Ben Philpot (June 2020), with operational support from partners including the Eshelman Institute for Innovation.

Pinnacle Hill does not commercialize products directly. Its economic model rests on Deerfield's capital commitment, profit-sharing with UNC-Chapel Hill on successful projects, and Deerfield's option to make additional investments into spin-off companies that emerge from the partnership. Customer engagement is conducted through direct outreach, group information sessions, and one-on-one discussions with UNC faculty rather than conventional sales channels. The company is pre-revenue and serves as an internal R&D engine for its two parent organizations rather than an independent commercial enterprise.

Name

Pinnacle Hill

Legal name

Pinnacle Hill, LLC

Website

https://pinnacle-hill.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

51–100 employees

Short description

Pinnacle Hill is a pre-revenue drug discovery partnership between UNC-Chapel Hill and Deerfield Management, funding translational small molecule research at UNC with up to $65 million in targeted capital and operational drug development support.

Ownership category

akta.pro rank

Product category

Pharmaceutical R&D Services

NAICS

Grantmaking Foundations (813211), Research and Development in the Social Sciences and Humanities (54172)

akta.pro primary industry

Health & Medical Research Grantmaking Foundations (BPAGAKAL)

akta.pro secondary industry

Results-Based Financing (RBF) & Performance-Based Grants (BPADAOAF)

Keywords

• Drug discovery research
• Translational research funding
• Academic-industry partnership
• Small molecule therapeutics
• Investigational new drug

Headquarters

HQ city

England

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations

Core offering

Pinnacle Hill is a research and development partnership between the University of North Carolina at Chapel Hill and Deerfield Management that funds and supports drug discovery projects. The entity funds IND-enabling studies and provides expert drug development guidance, project management oversight, and business strategy to accelerate the translation of academic research into clinical therapeutics. Projects are approved and directed by a joint steering committee, with profits shared between Deerfield and UNC-Chapel Hill.

Product overview

Pinnacle Hill is a single unified research partnership entity focused on accelerating the translation of academic scientific discoveries into clinical therapeutics. The company operates through a joint steering committee model where UNC-Chapel Hill and Deerfield Management jointly approve and direct drug research projects. Each selected project receives funding and expert drug development guidance to support investigational new drug enabling studies. The company has funded two initial projects: one focused on multiple myeloma (led by Lindsey James) and one on Angelman syndrome (led by Ben Philpot).

Differentiator

Problem solved

Functional benefit

Products and services

• Pinnacle Hill Drug Research Partnership A joint venture between UNC-Chapel Hill and Deerfield Management that funds and supports drug discovery research projects. The partnership approves and directs research through a joint steering committee, providing funding and drug development expertise to advance promising therapeutic research projects at UNC-Chapel Hill.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Four partnerships are on record, tiered minor and core.

• Lindsey James (UNC-Chapel Hill)minorStrategic or Co-development Partner · 1 December 2019Lindsey James, Assistant Professor in the UNC Eshelman School of Pharmacy's chemical biology and medicinal chemistry division, leads the multiple myeloma project. Her work focuses on epigenetic abnormalities that lead to cancer, applying medicinal chemistry, chemical biology, and cancer biology approaches to discover potential therapeutic agents for multiple myeloma.
• Ben Philpot (UNC-Chapel Hill)minorStrategic or Co-development Partner · 1 June 2019Ben Philpot, Kenan Distinguished Professor and associate director of the UNC Neuroscience Center, leads the Angelman syndrome project funded by Pinnacle Hill. His work focuses on developing small molecule treatments for Angelman syndrome, a neuro-genetic disorder. The Pinnacle Hill team works intimately with Philpot's lab along with collaborators Jeff Aube at UNC Eshelman School of Pharmacy and Stormy Chamberlain at University of Connecticut.
• University of North Carolina at Chapel Hill (UNC-Chapel Hill)coreStrategic or Co-development Partner · 1 October 2018UNC-Chapel Hill is the academic partner in the Pinnacle Hill collaboration. The partnership brings together UNC's world-class life sciences research expertise with Deerfield's funding and drug development expertise. Research and development conducted at Pinnacle Hill is supported by funding, expert drug development guidance, experienced project management oversight, and business strategy. Projects are approved and directed by a joint steering committee. Profits from successful projects are shared by Deerfield and UNC-Chapel Hill.
• Eshelman Institute for InnovationcoreStrategic or Co-development PartnerThe Eshelman Institute for Innovation at UNC Eshelman School of Pharmacy is a key partner in the Pinnacle Hill collaboration. Established in 2014 with a $100 million gift from Dr. Fred Eshelman, the Institute aims to accelerate the creation and development of ideas leading to discoveries of new medicines and technologies. John Bamforth serves as director and is a member of the Pinnacle Hill joint steering committee.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Flagship Pioneering: Biotech venture creation firm that originates and develops first-in-class therapeutics from academic and scientific research. Comparable venture-creation playbook with multi-program platform approach.
• ARCH Venture Partners: Long-tenured biotech VC that has spun out numerous companies from university research, including foundational platforms in genomics and drug discovery. Comparable academic spinout creation focus.
• Versant Ventures: Healthcare-focused venture firm known for its in-house company creation platform (Inception Sciences) that builds companies from academic research. Comparable academic-to-biotech translation model.
• Eshelman Institute for Innovation: UNC Eshelman School of Pharmacy institute that funds translational pharmaceutical research, including co-funding projects through Pinnacle Hill. Operates an adjacent model at the same institution and shares leadership on Pinnacle Hill's joint steering committee.
• Atlas Venture: Early-stage venture firm that builds biotech companies from academic science, frequently pairing pharma-industry leaders with academic PIs in a venture-creation model. Highly comparable to Pinnacle Hill's academic-to-company pipeline approach.
• Cure. (Deerfield affiliate): Deerfield-affiliated healthcare innovation ecosystem that accelerates cures from concept to commercialization. It is the most direct peer because it shares parent organization (Deerfield Management), the same translational research mission, and overlapping leadership and infrastructure.
• Accelerator Life Science Partners: Investment and operating partner that builds and grows early-stage biotechnology companies by pairing scientific founders with industry expertise. Directly mirrors Pinnacle Hill's pharma-expert-plus-academic-PI structure.

Broad incumbents

• BridgeBio Pharma: Commercial-stage genetic disease drug developer founded on translational research from academic labs. Broader but comparable — translates academic discoveries into clinical assets with a multi-program portfolio strategy.

Others

• Wellcome Trust: Large charitable foundation that funds biomedical research and translational science. Comparable as a research-funder with translational mandate, though operating at much larger scale and primarily grantmaking rather than direct company creation.
• Howard Hughes Medical Institute: Large biomedical research organization that funds and operates academic research labs. Thematically comparable as a research-funding and research-performing institution, but does not pursue drug commercialization directly.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pinnacle Hill